SC
BIVV

Samlyn Capital’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Samlyn Capital’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-272,800
Closed -$14.9M – 166
2017
Q1 		$14.9M Buy
+272,800
New +$13.4M 0.34% 81

Other funds holding BIVV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.63B AUM 5.11% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Samlyn Capital's BIVV Position: Q2 2017 in Review

Samlyn Capital sold out of Bioverativ Inc. Common Stock (BIVV) in Q2 2017, closing a stake of 272,800 shares — an estimated $14.9M sold.

Samlyn Capital first reported a position in BIVV in Q1 2017 and held it in 1 quarter. The position peaked at $14.9M in Q1 2017. 452 funds tracked by Wall St. Rank hold BIVV as of Q2 2017.

  • Samlyn Capital reported no remaining Bioverativ Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Samlyn Capital sold 272,800 Bioverativ Inc. Common Stock shares in Q2 2017, an estimated $14.9M.
  • Samlyn Capital first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Samlyn Capital's Bioverativ Inc. Common Stock position peaked at $14.9M in Q1 2017.
  • 452 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q2 2017.

Based on Samlyn Capital's 13F filing for Q2 2017, filed 14 Aug 2017.